The Jackson Laboratory And Caribou Biosciences Announce CRISPR-Cas9 License Agreement
Bar Harbor, ME and Berkeley, CA – Caribou Biosciences, Inc. and The Jackson Laboratory (JAX) announced an agreement today whereby Caribou has granted JAX non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes.
Caribou's market-leading CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise and controllable changes to the genome. This agreement further strengthens JAX’s leadership in applying gene editing technology to create mouse models that better recapitulate human diseases enabling researchers to find better treatments faster.
"JAX is excited to reach this CRISPR-Cas9 IP agreement with Caribou," said Edison Liu, M.D., president and CEO of JAX. "CRISPR technology has transformed genetic engineering in nearly all biological systems. This license allows us to deliver custom-built mouse models, creating the next generation of predictive models for the new era of personalized medicine."
"We are delighted to enter into this agreement with JAX, a recognized leader in genomic research” said Dr. Rachel Haurwitz, President and CEO of Caribou. "We strive to bring the countless benefits of our CRISPR-Cas9 technology to the research community in a broad manner and we believe our relationship with JAX represents an important vehicle to help achieve this goal."
The license from Caribou includes CRISPR-Cas9 technology and intellectual property owned by Caribou as well as foundational CRISPR-Cas9 intellectual property exclusively licensed to Caribou by The Regents of the University of California and the University of Vienna.
About Caribou Biosciences, Inc.
Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies located in Berkeley, California. The company was founded by pioneers of CRISPR-Cas biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, visit www.cariboubio.com and follow the company @CaribouBio. “Caribou Biosciences” and Caribou’s logo are trademarks of Caribou Biosciences, Inc.
Caribou Biosciences Media Contact:
Jessi Rennekamp
Feinstein Kean Healthcare
952-649-8600 jessi.rennekamp@fkhealth.com
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,800 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.
Caribou's market-leading CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise and controllable changes to the genome. This agreement further strengthens JAX’s leadership in applying gene editing technology to create mouse models that better recapitulate human diseases enabling researchers to find better treatments faster.
"JAX is excited to reach this CRISPR-Cas9 IP agreement with Caribou," said Edison Liu, M.D., president and CEO of JAX. "CRISPR technology has transformed genetic engineering in nearly all biological systems. This license allows us to deliver custom-built mouse models, creating the next generation of predictive models for the new era of personalized medicine."
"We are delighted to enter into this agreement with JAX, a recognized leader in genomic research” said Dr. Rachel Haurwitz, President and CEO of Caribou. "We strive to bring the countless benefits of our CRISPR-Cas9 technology to the research community in a broad manner and we believe our relationship with JAX represents an important vehicle to help achieve this goal."
The license from Caribou includes CRISPR-Cas9 technology and intellectual property owned by Caribou as well as foundational CRISPR-Cas9 intellectual property exclusively licensed to Caribou by The Regents of the University of California and the University of Vienna.
About Caribou Biosciences, Inc.
Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies located in Berkeley, California. The company was founded by pioneers of CRISPR-Cas biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, visit www.cariboubio.com and follow the company @CaribouBio. “Caribou Biosciences” and Caribou’s logo are trademarks of Caribou Biosciences, Inc.
Caribou Biosciences Media Contact:
Jessi Rennekamp
Feinstein Kean Healthcare
952-649-8600 jessi.rennekamp@fkhealth.com
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,800 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.